CN1695708A - Compound longxuejie preparation, preparing technique and application - Google Patents
Compound longxuejie preparation, preparing technique and application Download PDFInfo
- Publication number
- CN1695708A CN1695708A CN 200510018777 CN200510018777A CN1695708A CN 1695708 A CN1695708 A CN 1695708A CN 200510018777 CN200510018777 CN 200510018777 CN 200510018777 A CN200510018777 A CN 200510018777A CN 1695708 A CN1695708 A CN 1695708A
- Authority
- CN
- China
- Prior art keywords
- longxuejie
- radix salviae
- preparation
- sanguis draxonis
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating coronary heart disease, angina pectoris, etc is prepared from Dragon's blood, red sage root, astragalus root, Chuan-xiong rhizome, gingko and borneol proportionally.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation and preparation method thereof and application, particularly compound longxuejie preparation and preparation technology thereof and application.
Background technology
Cardiovascular disease is important clinically common frdquently encountered disease, has anxious, the characteristics such as change of illness state is fast, mortality rate height of morbidity.Coronary heart disease, hypertensive cardiopathy are that the painstaking effort tubing disease of seeing is planted more, and the M ﹠ M of these two kinds of diseases is also rising, and ordinary circumstance is that height is handed in developed regions, and is remote lower with backward areas, illustrates that this type of disease and people's living standard has certain proportional relationship.Indicating that this type of disease is just becoming a serious killer of China's people's life.
Now the Chinese medicine of treatment similar disease is also many, but is to make with crude drug mostly, and active component is low, and drug effect is slow, the efficacy of a drug a little less than.As FUFANG DANSHEN PIAN is that the former medicated powder of Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum mixes after broken, and effective ingredient is very low, and drug effect clinically is slow, and the patient will take heavy dose of tablet just can be effective.
In recent years to the hematology aspect research prompting of ischemic cerebrovascular: blood aspect unusual, especially thrombosis is a major reason of ischemic cerebrovascular.Causing the thrombosed condition of cerebrovascular mainly is the tunica intima damage, and this is the fundamental prerequisite of vascularization thrombosis.Sanguis Draxonis, Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Chuanxiong, Semen Ginkgo, Fructus Crataegi total flavones, Borneolum Syntheticum can significantly suppress rat arteriovenous shut thrombosis, and the weight in wet base of thrombosis and dry weight are significantly reduced, and alleviate brain injury.
Summary of the invention
New Chinese medicine preparation of the treatment cardiovascular disease that the objective of the invention is to propose that a kind of cost is low, drug effect is high, has no side effect and preparation method thereof and application: this Chinese medicine preparation is a compound dragon's blood, mainly contains Sanguis Draxonis and Radix Salviae Miltiorrhizae composition.
Technical scheme of the present invention is:
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: Sanguis Draxonis 2-100 part, Radix Salviae Miltiorrhizae 2-200 part, Radix Astragali 0-60 part, Rhizoma Chuanxiong 0-60 part, Semen Ginkgo 0-60 part, Borneolum Syntheticum 0-30 part.
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: Sanguis Draxonis 20-100 part, Radix Salviae Miltiorrhizae 20-200 part, Radix Astragali 0-60 part, Rhizoma Chuanxiong 0-60 part, Semen Ginkgo 0-60 part, Borneolum Syntheticum 0-30 part.
Compound longxuejie preparation, it comprises that also the raw material of following weight portion makes: Fructus Crataegi total flavones 1-60 part.
The preparation method of compound longxuejie preparation is chosen qualified Folium Dracaenae cambodianae and Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Chuanxiong, Semen Ginkgo pulverizing respectively, mixes or separate effective component extracting; With the Sanguis Draxonis of purification and one or more mixing in Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Chuanxiong, Semen Ginkgo extrac and the Fructus Crataegi total flavones; Packing after will going up step products obtained therefrom packing or adding mixed micro-Borneolum Syntheticum powder.
Compound longxuejie preparation, said preparation are any one in capsule, tablet, granule, oral liquid, drop pill, aqueous injection and the injectable powder.
Following 2 points that should illustrate: in view of the multiformity of pharmaceutical dosage form and production technology, and consider acceptance and the using method of patient to medicine, composite reagent of the present invention can be made capsule, tablet, granule, oral liquid, drop pill, aqueous injection and injectable powder by above-mentioned prescription and Technology thereof.In view of pharmaceutical dosage form and the needs that produce to use, can be on the basis of above-mentioned prescription reasonable pharmaceutic adjuvants such as absorb fillers, excipient, pH value regulator, correctives, cosolvent, antioxidant, to satisfy drug manufacture and use.
The application of compound longxuejie preparation in the medicine that suppresses venous thrombosis.
The application of compound longxuejie preparation in the medicine that suppresses focal cerebral ischemia.
Sanguis Draxonis can make rat acute Blood stasis hemorheology change, and strengthens rabbit isolated heart coronary flow; The rabbit that total flavone in Sanguis Draconis causes glucose " stasis syndrome " model can obviously reduce its whole blood viscosity, plasma viscosity and packed cell volume; Shorten erythrocyte electrophoretic time; The platelet aggregation and the experimental thrombosis that can also obviously suppress rat form.The Sanguis Draxonis toxicity test shows: aspect the long term toxicity test of 90d, Sanguis Draxonis does not cause the change of animal pathological state, and infringement is not seen in erythrocyte, leukocytic growth regulating liver-QI, renal function aspect; Pathologic finding under optical microscope, tiny blood vessels has certain expansion except that between visible myocardial cell, to the harmless effect of spleen, liver, lung, kidney, intestinal and adrenal gland.Toxic reaction does not appear in rat ig30d.
Radix Salviae Miltiorrhizae has appreciable impact to thrombosis, total salvianolic acid to cerebral ischemia after the PG metabolism certain influence is arranged, reduce TXB2 content in the blood, but 6-ketone-PGF1a content do not had influence, improve PGI2/TXA2 ratio, reduce thrombotic probability.60min behind rat and the mouse mainline Tanshinone I I-A sodium sulfonate 12.5-38mgkg-1, the external thrombus formation time prolongs, the thrombosis contraction in length, thrombosis is done, weight in wet base alleviates, platelet adhesion and aggregation capability reduce, and recalcification time, prothrombin time and KPTT can't present obvious inhibition.Mechanism of action may to suppress the activated Mg+-ATP enzyme activity of actin relevant for Radix Salviae Miltiorrhizae, and Tanshinone I I-A has the noncompetitive inhibitory action to this enzyme.Total salvianolic acid (12.5,25mgkg-1, ip) show the dose-dependent inhibition effect to experimental in body thrombosis, the matched group wet weight of thrombus is 27.99mg, total salvianolic acid various dose group is respectively 17.93mg and 19.76mg, relatively having significant difference (P＜0.05) salvianolic acid can influence prostaglandin metabolism with matched group, may be one of its antithrombotic mechanism of action.Salvianolic acid B can increase fibrinolysis, and certain fibrinolytic effect is arranged, and may be an aspect factor of its anti-thrombosis function.
Rhizoma Chuanxiong is adjusted effects such as TXA2/PGL2 by antiplatelet aggregation, blood vessel dilating, reduction whole blood viscosity, reaches anti thrombotic action.Diseases such as prevention and treatment coronary heart disease, pulmonary heart disease, cerebral thrombosis, renal failure.Rhizoma Chuanxiong extract can make the ET level descend, and can expand little artery and vein, indirect inhibition.
The Radix Astragali has the anti peroxidation of lipid thing and removes the oxygen-derived free radicals effect, thereby has reduced former and secondary injury of brain cell after the infarction.Simultaneously, the Radix Astragali still has anticoagulant, blood vessel dilating, microcirculation improvement, low temperature resistant, anoxia enduring, effects such as enhancing body stress ability, thus reach the purpose for the treatment of ischemic cerebrovascular.
The effective ingredient that extracts in the Folium Ginkgo is mainly ginkgetin glycosides and ginkgolide, acts on ischemic treatment of cerebral mechanism: improve hemorheology, be beneficial to microcirculatory unobstructed; Increase the cerebral blood flow velocity of cerebral ischemia hemisphere, increase the local cerebral blood flow supply; Improve the brain cortex hormone function, correct the ischemia injury of brain electricity, promote the recovery of function of nervous system etc.
Fructus Crataegi total flavones can increase coronary flow anti-experimental character myocardial ischemia, effects such as anti-heart string disppointment, Fructus Crataegi total flavones no matter in the body or treated in vitro all can significantly suppress the rabbit platelet aggregation, this control to cardiovascular disease such as coronary heart disease obviously is useful, can also make vasodilation, help to remove local pound blood state, and the effect of shrinking the uterus, promoting uterine involution is arranged.
Effect of the present invention is seen following experimental example:
Experimental example 1: Sanguis Draxonis extract adds the influence of Radix Salviae Miltiorrhizae extract to the rat experiment venous thrombosis
Experiment grouping and dosage design, laboratory animal is divided into 7 groups at random:
1. animal pattern is organized: 20 of laboratory animals.Gavage 0.25%CMC (solvent control) every day, 1ml/100g body weight, continuous 2 weeks.
2. positive drug SHUXUENING group: 15 of laboratory animals.Gavage SHUXUENING 80mg/kg body weight every day, continuous 2 weeks.
3. Sanguis Draxonis extract dosage group: 15 of laboratory animals.Gavage Sanguis Draxonis extract 160mg/kg body weight every day, continuous 2 weeks.
4. Radix Salviae Miltiorrhizae extract dosage group: 15 of laboratory animals.Gavage Radix Salviae Miltiorrhizae extract 160mg/kg body weight every day, continuous 2 weeks.
5. Sanguis Draxonis extract adds the Radix Salviae Miltiorrhizae extract high dose group: 15 of laboratory animals.Gavage Sanguis Draxonis extract every day and add Radix Salviae Miltiorrhizae extract 160mg/kg body weight, continuous 2 weeks.
6. Sanguis Draxonis extract adds dosage group in the Radix Salviae Miltiorrhizae extract: 15 of laboratory animals.Gavage Sanguis Draxonis extract every day and add Radix Salviae Miltiorrhizae extract 80mg/kg body weight, continuous 2 weeks.
7. Sanguis Draxonis extract adds the Radix Salviae Miltiorrhizae extract low dose group: 15 of laboratory animals.Gavage Sanguis Draxonis extract every day and add Radix Salviae Miltiorrhizae extract 40mg/kg body weight, continuous 2 weeks.
Experimental procedure, after the last administration 1 hour, with pentobarbital sodium (40mg/kg, in) anesthesia, open abdomen and separate postcava, in the left renal vein below with cordonnet ligation postcava.Since the venous blood flow blocking-up, thrombosis.Sew up stomach wall, opened abdomen again in 4 hours after the ligation, 2cm place folder closes blood vessel below ligation, cuts tube chamber open, and removal of thromboses claims weight in wet base, claims dry weight after the drying again.Average,, compare between organizing through the t check.
Experimental result sees Table 1.
Table 1 Sanguis Draxonis extract adds Radix Salviae Miltiorrhizae extract to the rat experiment venous thrombosis
Influence (X ± SD)
| Group | Number of animals (only) | (X ± SD) and weight reduce percentage rate (%) to thrombus weight | |||
| Weight in wet base (mg) | Reduce (%) | Dry weight (mg) | Reduce (%) | ||
| Model group positive drug group dragon's blood exhausts alcohol extract group Salvia root P.E group dragon's blood extract and adds Salvia root P.E high dose group dragon's blood extract and add that dosage group dragon's blood extract adds the Salvia root P.E low dose group in the Salvia root P.E | ???18 ???15 ? ???15 ???15 ? ???15 ? ? ???14 ? ? ???14 ? | 18.6±5.4 7.8±4.0※ ※ 14.3±6.7 15.5±7.0 6.5±4.3※ ? ※ 8.0±4.1※ ? ※ 10.5±4.5※ ? ※ | ? ????58.1 ? ????23.1 ????16.7 ? ????65.1 ? ? ????57.0 ? ? ????43.5 ? | 6.3±2.1 3.0±1.6※ ※ 5.3±2.2 5.6±2.4 2.2±1.1※ ? ※ 3.1±1.3※ ※ 4.0±1.8※ ? ※ | ? ????52.4 ? ????15.9 ????11.1 ? ????65.1 ? ? ????50.8 ? ? ????36.5 ? |
Annotate:, compare ※ ※ P＜0.01 with the animal pattern group through the t check.
Sanguis Draxonis extract of the present invention adds the high, medium and low dosage group of Radix Salviae Miltiorrhizae extract in the contrast experiment who reduces the rat experiment venous thrombosis, and effect is better than the effect among the contrast experiment of reduction rat experiment venous thrombosis of " 02129688.X Sanguis Draxonis flavoniod preparation technology and new purposes thereof " record.
Sanguis Draxonis extract adds Radix Salviae Miltiorrhizae extract 160mg/kg body weight and 80mg/kg body weight, in 1 week of continuous irrigation stomach, can obviously suppress the rat experiment venous thrombosis.The weight in wet base of thrombosis, dry weight are compared with the model group animal all has tangible reduction (P＜0.01), and certain dose-effect relationship is arranged, Sanguis Draxonis extract adds Radix Salviae Miltiorrhizae extract 40mg/kg body weight group, and the weight in wet base of laboratory animal thrombosis, dry weight are compared with the model group animal, reduces not obvious (P＞0.05).The curative effect that Sanguis Draxonis extract adds Radix Salviae Miltiorrhizae extract 80mg/kg body weight is suitable with the positive control drug SHUXUENING.
Experimental example 2: Sanguis Draxonis extract adds Radix Salviae Miltiorrhizae extract to the behavior of focal rats with cerebral ischemia and the influence of brain tissue impairment
Laboratory animal is divided into 7 groups at random, that is:
1. model group (solvent control, n=13): gavage 0.25%CMC every day, 0.5ml/100g body weight, continuous 4 days.Duplicate the focal cerebral ischemia model by method 3.2 behind the last administration 15min.
2. sham operated rats (n=6): gavage 0.25%CMC every day, 0.5ml/100g, continuous 4 days.The isotype type group of operation behind the last administration 15min, but plug wire not.
3. nimodipine group (n=10): gavage nimodipine 5mg/kg body weight every day, 0.5ml/100g, continuous 4 days.The isotype type group of operation behind the last administration 15min.
4. NAODESHENG group (n=10): gavage NAODESHENG 2.7g/kg body weight every day, 0.5ml/100g, continuous 4 days.The isotype type group of operation behind the last administration 15min.
5. Sanguis Draxonis extract adds the heavy dose of group of Radix Salviae Miltiorrhizae extract (n=15): gavage Sanguis Draxonis extract every day and add Radix Salviae Miltiorrhizae extract 100mg/kg body weight, 0.5mi/100g, continuous 4 days.The isotype type group of operation behind the last administration 15min.
6. Sanguis Draxonis extract adds dosage group (n=10) in the Radix Salviae Miltiorrhizae extract: gavage Sanguis Draxonis extract every day and add Radix Salviae Miltiorrhizae extract 50mg/kg body weight, 0.5ml/100g, continuous 4 days.The isotype type group of operation behind the last administration 15min.
7. Sanguis Draxonis extract adds Radix Salviae Miltiorrhizae extract small dose group (n=8): gavage Sanguis Draxonis extract every day and add Radix Salviae Miltiorrhizae extract 25mg/kg body weight, 0.5ml/100g, continuous 4 days.The isotype type group of operation behind the last administration 15min.
The focal cerebral ischemia in rats model
With reference to the LOnga method, block middle cerebral artery (MCA) and cause the focal cerebral ischemia in rats model.Get the SD rat, (350mg/kg ip), faces upward the position and fixes the chloral hydrate anesthesia with 10%, cuts skin and subcutaneous tissue along cervical midline, separates in right carotid and the neck thereof and branch outside the neck.Ligation neck summation external carotid artery, the bulldog clamp folder closes internal carotid artery, cuts off the common carotid artery distal end, is the nylon wire insertion common carotid artery of 0.26mm with diameter, passes in the neck and enters internal carotid artery with notable and rashing pulsation of common carotid artery arteries and veins crotch.
Unclamp bulldog clamp, continue line is inserted into the intracranial segment of internal carotid artery.When feeling obvious resistance, the total length that insert line this moment is about 2.0cm, MCA promptly capable of blocking.The ligation plug wire is with slip-off preventing, skin suture.
Function of nervous system's behavior scoring and cerebral infarction scope are measured
Behind the cerebral ischemia 24h, function of nervous system's behavior of rat is marked.Scoring is carried out with reference to the method for Bederson and Lin.Concrete grammar following (total points is 11 minutes): 1. mention Mus tail built on stilts, observe the forelimb situation.Normal rat two forelimbs stretch to ground symmetrically.Appearance wrist song, elbow song, shoulder inward turning person are chosen as 1～3 fen respectively, occur shoulder inward turning companion's wrist song or elbow song person simultaneously and are chosen as 4 fens.2. with on the sliding floor of rat horizontalization, push away a left side (or right) shoulder respectively and check the resistance that opposing promotes to side shifting.Normal rat bilateral resistance is symmetry obviously.When right shoulder is mobile to the left, find the resistance descender, according to descend light, in, heavy degree, be chosen as 1～3 fen respectively.3. rat two forelimbs are put on the wire netting, observed the muscular tension of two forelimbs.Normal rat two muscle of anterior limb tension force are symmetry obviously.Find left fore muscular tension descender, according to descend light, in, heavy degree, be chosen as 1～3 fen respectively.4. rat is put on the floor, observe its walking.The person occurs obviously not turn-taking, be chosen as 1 fen, otherwise 0 minute.Mark is high more, illustrates that the behavior disorder of animal is serious more.Single blind method is adopted in scoring.
The cerebral infarction scope is measured and is adopted the TIC staining.Behind the cerebral ischemia 24h, rat broken end is got brain, removes olfactory bulb, cerebellum and low brain stem, is cut into 5 with forebrain is crown.Slice position is: locate between the utmost point and optic chiasma line mid point, optic chiasma position, infundibular stalk position and infundibular stalk and the back utmost point before the brain.The brain sheet is immersed in the 5mlTTC dyeing liquor (comprising 4%TTC 1.5ml, 1m01/LK2HPO40.1ml and distilled water 3.4ml) 37 ℃ of lucifuge dyeing 30min.Take a picture then, computer analysis obtains the percentage ratio that the infarcted region area accounts for the forebrain hemisphere gross area, represents the cerebral infarction scope.
Statistical procedures, all data are all represented with mean+SD.Relatively check between two groups with t.
The result
1, Sanguis Draxonis extract add Radix Salviae Miltiorrhizae extract to focal cerebral ischemia after the influence of function of nervous system's behavior scoring
After middle cerebral artery blocking-up 24h caused focal cerebral ischemia, model group rat left fore muscular tension descended, and performance left fore wrist song, trunk song, shoulder inward turning and curable grip descend, and it is 8.6 minutes that function of nervous system all marks.The sham operated rats part animal left fore muscular tension also tip has decline, and function of nervous system's average score is 2.2 minutes, is starkly lower than model group 9＜0.01).Sanguis Draxonis extract adds after Radix Salviae Miltiorrhizae extract 100,50,25mg/kg body weight, nimodipine 5mg/kg body weight or the administration of NAODESHENG 2.7g/kg body weight function of nervous system's behavior scoring descend respectively 22.7%, 16.0% (P＜0.01), 13.6% (P＜0.05), 13.6% and 9.1%.
The results are shown in Table 2.
Table 2 Sanguis Draxonis extract add Radix Salviae Miltiorrhizae extract to focal cerebral ischemia after the influence of function of nervous system's behavior scoring
| Grouping | Dosage (mg/kg) | Number of animals (only) | Function of nervous system's behavior scoring (X ± SD) | Medicine group decline percentage rate (%) |
| Model group sham-operation group Nimodipine group brain must be given birth to dosage group sample small dose group in the heavy dose of group of the group sample sample | ????- ????- ????5 ????2700 ????100 ????50 ????25 | ????13 ????6 ????10 ????10 ????15 ????10 ????8 | ?????8.8±1.4 ?????2.1±2.3※※ ??????????7.6±1.2 ?????8.0±1.8 ?????6.8±1.5 ?????7.4±0.9※※ ??????????7.6±0.5※※ | ????????- ????????- ???????13.6 ???????9.1 ???????22.7 ???????16.0 ???????13.6 |
Annotate:, compare ※ p＜0.05, ※ ※ p＜0.01 with model group through the t check.
Sanguis Draxonis extract of the present invention adds among the contrast experiment of the high, medium and low dosage group of Radix Salviae Miltiorrhizae extract function of nervous system's behavior after to focal cerebral ischemia, effect be better than " 02129688.X Sanguis Draxonis flavoniod preparation technology and new purposes " record to the effect among the contrast experiment of function of nervous system's behavior behind the focal cerebral ischemia.
2, Sanguis Draxonis extract add Radix Salviae Miltiorrhizae extract to focal cerebral ischemia hindbrain infarction size influence middle cerebral artery blocking-up 24h after, visible significantly cerebral tissue ischemic infarction district (position of being unstained).Model group rat cerebral infarction scope accounts for 28.0% of forebrain hemisphere area.Sanguis Draxonis extract adds Radix Salviae Miltiorrhizae extract 100,50,25mg/kg body weight, nimodipine 5mg/kg body weight or NAODESHENG 2.7g/kg body weight administration hindbrain infarction size and reduces 21.4%, 41.3% (p＜0.01), 38.4% (p＜0.01), 29.5% (p＜0.05) and 25.6% respectively.
The results are shown in Table 3.
Table 3 Sanguis Draxonis extract adds Radix Salviae Miltiorrhizae extract to focal cerebral ischemia hindbrain infarction size
Influence
| Grouping | Dosage (mg/kg) | Number of animals (only) | Cerebral infarction scope (%) (X ± SD) | Medicine group decline percentage rate (%) |
| Model group Nimodipine group brain must be given birth to dosage group sample small dose group in the heavy dose of group of the group sample sample | ????- ????5 ????2700 ????100 ? ????50 ? ????25 | ????13 ????10 ????10 ????15 ? ????10 ? ????8 | 28.1±5.8 19.8±8.0※ 20.9±10.2 22.1±10.3 16.5±10.6※ ? ※ 17.3±8.2※ | ???????- ??????29.5 ??????25.6 ??????21.4 ? ??????41.3 ? ??????38.4 |
Annotate:, compare ※ p＜0.05, ※ ※ p＜0.01 with model group through the t check.
Experimental result shows that behind the cerebral ischemia 24h, the left fore muscular tension of model group rat obviously descends, and function of nervous system's behavior scoring is 8.6 minutes: tangible ischemic infarction district appears in cerebral tissue dyeing, accounts for 28.0% of forebrain hemisphere area.Sanguis Draxonis extract adds Radix Salviae Miltiorrhizae extract 50,25mg/kg body weight, continuous irrigation stomach 4 days.Can significantly reduce function of nervous system's behavior scoring (p＜0.01 or p＜0.05) of rat, and obviously reduce cerebral infarction scope (p＜0.01), curative effect is better than positive control drug nimodipine 5mg/kg body weight and NAODESHENG 2.7g/kg body weight.
The specific embodiment:
Embodiment 1
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 60 parts of Sanguis Draxonis, 30 parts of Radix Salviae Miltiorrhizaes.
Red rooted salvia is ground into middle powder, adds 6 times of amount 90% ethanol percolations, water precipitating, supernatant is concentrate drying routinely, obtains fine powder; Medicinal residues add 10 times of water gagings, extract 2 times, and each 1.5 hours, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains the Radix Salviae Miltiorrhizae fine powder routinely.
Resina Draconis-drug is ground into middle powder, adds 6 times of amount 90% ethanol percolations, water precipitating, supernatant is concentrate drying routinely, obtains fine powder; Medicinal residues add 10 times of water gagings, extract 2 times, and each 1.5 hours, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains the Sanguis Draxonis fine powder routinely.
Add conventional adjuvant respectively, obtain in compound longxuejie preparation capsule, tablet, granule, oral liquid, drop pill, aqueous injection and the injectable powder any one according to a conventional method.
Embodiment 2
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 80 parts of Sanguis Draxonis, 50 parts of Radix Salviae Miltiorrhizaes.
Adopt the preparation method of Radix Salviae Miltiorrhizae in the GUANXIN DANSHEN PIAN that 2005 editions P550 provide to obtain the Radix Salviae Miltiorrhizae fine powder.
All the other are with embodiment 1.
Embodiment 3
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 70 parts of Sanguis Draxonis, 80 parts of Radix Salviae Miltiorrhizaes.
Get the Sanguis Draxonis section, water decocts three times, 2 hours for the first time, second and third time each 1 hour, collecting decoction filters, filtrate is concentrated into relative density 1.05-1.10 (80 ℃ of surveys), adds the 2mol/L hydrochloric acid solution and regulate pH value to 1.0-2.0 in the time of 80 ℃, is incubated 1 hour, left standstill 24 hours, and filtered, precipitation washes with water to pH value 5.0, continuing and being washed till pH value with 70% ethanol is 7.0, cold drying is ground into the Sanguis Draxonis fine powder, and is standby.
All the other are with embodiment 1.
Embodiment 4
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 100 parts of Sanguis Draxonis, 160 parts of Radix Salviae Miltiorrhizaes, 60 parts of Rhizoma Chuanxiongs.
Get red sage and chuanxiong rhizome and be broken into fine powder/be ground into coarse powder/be cut into decoction pieces, decoct with water each 1-3 hour 2-3 time, collecting decoction filters, and filtrate is concentrated to relative density and is about 1.15-1.30 (70-80 ℃), wait to be chilled to 40 ℃, add ethanol and make and contain alcohol amount and reach 75%, left standstill 6-24 hour, it is an amount of that leaching supernatant, residue add 75% ethanol, left standstill 6-24 hour, filter, merge ethanol liquid, reclaim ethanol to there not being the alcohol flavor, and be concentrated into relative density 1.05-1.20 (60-65 ℃), be dried to extractum.
The method that provides by CN03135147.6 prepares the Sanguis Draxonis fine powder.
All the other are with embodiment 1.
Embodiment 5
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 25 parts of Sanguis Draxonis, 140 parts of Radix Salviae Miltiorrhizaes, 60 parts of the Radixs Astragali.
Sanguis Draxonis, Radix Salviae Miltiorrhizae, Milkvetch Root are ground into middle powder, add 6 times of amount 90% ethanol percolations, water precipitating, supernatant is concentrate drying routinely, obtains fine powder; Medicinal residues add 10 times of water gagings, extract 2 times, and each 1.5 hours, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains Sanguis Draxonis, Radix Salviae Miltiorrhizae, Radix Astragali fine powder routinely.
All the other are with embodiment 1.
Embodiment 6
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 50 parts of Sanguis Draxonis, 100 parts of Radix Salviae Miltiorrhizaes, 60 parts of Semen Ginkgoes.
The method that provides by CN94114835.1 prepares Semen Ginkgo extrac, and Semen Ginkgo extrac drying again obtains the Semen Ginkgo fine powder.
Embodiment 7
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 100 parts of Sanguis Draxonis, 70 parts of Radix Salviae Miltiorrhizaes, 30 parts of Borneolum Syntheticums.
The fine powder that Sanguis Draxonis, Radix Salviae Miltiorrhizae are obtained Sanguis Draxonis, Radix Salviae Miltiorrhizae by the method for embodiment 1 adds the Borneolum Syntheticum after the pulverizing, packing again.
All the other are with embodiment 1.
Embodiment 8
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 60 parts of Sanguis Draxonis, 100 parts of Radix Salviae Miltiorrhizaes, 10 parts of the Radixs Astragali, 20 parts of Rhizoma Chuanxiongs, 15 parts of Semen Ginkgoes, 5 parts of Borneolum Syntheticums.
Obtain the fine powder of Sanguis Draxonis by the method for embodiment 3.
Obtain the fine powder of Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong by the method for embodiment 4.
Obtain the fine powder of the Radix Astragali by the method for embodiment 5.
The method that provides by CN94114835.1 prepares Semen Ginkgo extrac, and Semen Ginkgo extrac drying again obtains the Semen Ginkgo fine powder.
All the other are with embodiment 7.
Embodiment 9
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 20 parts of Sanguis Draxonis, 20 parts of Radix Salviae Miltiorrhizaes, 18 parts of the Radixs Astragali, 30 parts of Rhizoma Chuanxiongs, 40 parts of Semen Ginkgoes, 20 parts of Borneolum Syntheticums.
All the other are with embodiment 8.
Embodiment 10
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 100 parts of Sanguis Draxonis, 2 parts of Radix Salviae Miltiorrhizaes.All the other are with embodiment 1.
Embodiment 11
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 2 parts of Sanguis Draxonis, 200 parts of Radix Salviae Miltiorrhizaes.All the other are with embodiment 1.
Embodiment 12
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 50 parts of Sanguis Draxonis, 40 parts of Radix Salviae Miltiorrhizaes, 5 parts of the Radixs Astragali, 10 parts of Rhizoma Chuanxiongs, 5 parts of Semen Ginkgoes, 5 parts of Borneolum Syntheticums, 60 parts of Fructus Crataegi total flavones.
The method that provides by CN03119429.X obtains Fructus Crataegi total flavones.
All the other are with embodiment 8.
Embodiment 13
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 5 parts of Sanguis Draxonis, 12 parts of Radix Salviae Miltiorrhizaes, 5 parts of the Radixs Astragali, 2 parts of Rhizoma Chuanxiongs, 2 parts of Semen Ginkgoes, 2 parts of Borneolum Syntheticums, 1 part of Fructus Crataegi total flavones.
The method that provides by CN91111834.9 obtains Fructus Crataegi total flavones.
All the other are with embodiment 8.
Embodiment 14
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 3 parts of Sanguis Draxonis, 5 parts of Radix Salviae Miltiorrhizaes, 1 part of the Radix Astragali, 2 parts of Rhizoma Chuanxiongs, 2 parts of Semen Ginkgoes, 1 part of Borneolum Syntheticum, 15 parts of Fructus Crataegi total flavones.
The method that provides by CN91111834.9 obtains Fructus Crataegi total flavones.
All the other are with embodiment 8.
Embodiment 15
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 80 parts of Sanguis Draxonis, 50 parts of Radix Salviae Miltiorrhizaes, 20 parts of the Radixs Astragali, 20 parts of Rhizoma Chuanxiongs, 10 parts of Semen Ginkgoes, 10 parts of Fructus Crataegi total flavones, 5 parts of Borneolum Syntheticums.
All the other are with embodiment 8.
Embodiment 16
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 60 parts of Sanguis Draxonis, 30 parts of Radix Salviae Miltiorrhizaes, 20 parts of the Radixs Astragali, 20 parts of Rhizoma Chuanxiongs, 10 parts of Fructus Crataegi total flavones, 5 parts of Borneolum Syntheticums.
All the other are with embodiment 8.
Embodiment 17
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 60 parts of Sanguis Draxonis, 40 parts of Radix Salviae Miltiorrhizaes, 20 parts of the Radixs Astragali, 10 parts of Fructus Crataegi total flavones, 5 parts of Borneolum Syntheticums.
All the other are with embodiment 8.
Embodiment 18
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 60 parts of Sanguis Draxonis, 40 parts of Radix Salviae Miltiorrhizaes, 30 parts of Rhizoma Chuanxiongs.
All the other are with embodiment 4.
Embodiment 19
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 60 parts of Sanguis Draxonis, 40 parts of Radix Salviae Miltiorrhizaes, 40 parts of the Radixs Astragali.
All the other are with embodiment 5.
Embodiment 20
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 60 parts of Sanguis Draxonis, 40 parts of Radix Salviae Miltiorrhizaes, 10 parts of Semen Ginkgoes.
All the other are with embodiment 6.
Embodiment 21
Compound longxuejie preparation, it mainly is to be made by the raw material of following weight portion: 60 parts of Sanguis Draxonis, 40 parts of Radix Salviae Miltiorrhizaes, 10 parts of Borneolum Syntheticums.
All the other are with embodiment 7.
Claims (7)
1, a kind of compound longxuejie preparation is characterized in that: it mainly is to be made by the raw material of following weight portion: Sanguis Draxonis 2-100 part, Radix Salviae Miltiorrhizae 2-200 part, Radix Astragali 0-60 part, Rhizoma Chuanxiong 0-60 part, Semen Ginkgo 0-60 part, Borneolum Syntheticum 0-30 part.
2, compound longxuejie preparation according to claim 1 is characterized in that: it mainly is to be made by the raw material of following weight portion: Sanguis Draxonis 20-100 part, Radix Salviae Miltiorrhizae 20-200 part, Radix Astragali 0-60 part, Rhizoma Chuanxiong 0-60 part, Semen Ginkgo 0-60 part, Borneolum Syntheticum 0-30 part.
3, compound longxuejie preparation according to claim 1 is characterized in that: it comprises that also the raw material of following weight portion makes: Fructus Crataegi total flavones 1-60 part.
4, the preparation method of claim 1,2,3 described compound longxuejie preparations is characterized in that: choose qualified Folium Dracaenae cambodianae and Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Chuanxiong, Semen Ginkgo pulverizing respectively, mix or separate effective component extracting; With the Sanguis Draxonis of purification and one or more mixing in Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Chuanxiong, Semen Ginkgo extrac and the Fructus Crataegi total flavones; Packing after will going up step products obtained therefrom packing or adding mixed micro-Borneolum Syntheticum powder.
5, according to claim 1,2,3 described compound longxuejie preparations, it is characterized in that: said preparation is any one in capsule, tablet, granule, oral liquid, drop pill, aqueous injection and the injectable powder.
6, claim 1,2, the application of 3 described compound longxuejie preparations in the medicine that suppresses venous thrombosis.
7, claim 1,2, the application of 3 described compound longxuejie preparations in the medicine that suppresses focal cerebral ischemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100187771A CN100457154C (en) | 2005-05-23 | 2005-05-23 | Compound longxuejie preparation, preparing technique and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100187771A CN100457154C (en) | 2005-05-23 | 2005-05-23 | Compound longxuejie preparation, preparing technique and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1695708A true CN1695708A (en) | 2005-11-16 |
| CN100457154C CN100457154C (en) | 2009-02-04 |
Family
ID=35348697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100187771A Expired - Fee Related CN100457154C (en) | 2005-05-23 | 2005-05-23 | Compound longxuejie preparation, preparing technique and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100457154C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244122B (en) * | 2008-03-04 | 2012-01-25 | 涿州东乐制药有限公司 | Pharmaceutical combination |
| CN102824516A (en) * | 2012-09-24 | 2012-12-19 | 李光 | Dragon's blood health wine with antithrombotic activity and preparation method thereof |
| CN106860729A (en) * | 2016-01-05 | 2017-06-20 | 云南大唐汉方制药股份有限公司 | A kind of Longxuejie Hanpian and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067891C (en) * | 1997-05-08 | 2001-07-04 | 曾力群 | Pure Chinese drug for curing cerebral thrambus |
-
2005
- 2005-05-23 CN CNB2005100187771A patent/CN100457154C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244122B (en) * | 2008-03-04 | 2012-01-25 | 涿州东乐制药有限公司 | Pharmaceutical combination |
| CN102824516A (en) * | 2012-09-24 | 2012-12-19 | 李光 | Dragon's blood health wine with antithrombotic activity and preparation method thereof |
| CN106860729A (en) * | 2016-01-05 | 2017-06-20 | 云南大唐汉方制药股份有限公司 | A kind of Longxuejie Hanpian and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100457154C (en) | 2009-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100339085C (en) | Combination of Chinese traditional medicine for curing cardiovascular and cerebrovascular diseases | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| KR20110132407A (en) | Plant extract compositions for prevention and treatment of influenza | |
| CN1304039C (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN101032580A (en) | Medicine for treating rheumatic diseases | |
| CN1494916A (en) | Chinese medicine composition for promoting bllod circulation and its preparation method | |
| CN1695708A (en) | Compound longxuejie preparation, preparing technique and application | |
| CN1813891A (en) | Perhexiline high-dose injection and its preparing method | |
| CN1698804A (en) | Chinese medicinal preparation for treating qi obstruction in chest and heart palpitation and its preparation process | |
| CN1672728A (en) | Extract of star of bethlehem and its prepn process, medicinal composition and use | |
| CN1188406C (en) | Cattail pollen extract and preparation process and use thereof | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1853689A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
| CN100341537C (en) | Composition for treatment of B-type hepatitis and liver cirrhosis | |
| CN1282470C (en) | Traditional Chinese medicine for anti depression | |
| CN1919252A (en) | Medicine for treating cardiovascular and cerebrovascular disease | |
| CN1679700A (en) | Medicinal preparation containing notoginseng and pueraria root for treating cardio-cerebral blood vessel diseases and its preparing method | |
| CN1887302A (en) | Application of spanishneedles herb flavonid in preparing medicine for preventing and treating liver fibrosis | |
| CN1919235A (en) | Cardiac and cerebral vascular disease treating pharmaceutical composition | |
| CN1919253A (en) | Cardiac and cerebral vascular disease treating medicinal composition | |
| CN1569184A (en) | Medicinal composition with ginseng and gingko leaf effective portion and its preparation mehtod | |
| CN1965849A (en) | Composition extracted from Chinese medicinals for treating coronary heart disease and method for preparing ingredients thereof | |
| CN1279919C (en) | Pharmaceutical compositions containing ginsenoside, safflor yellow and its preparation and application | |
| CN1772753A (en) | Chinese medicine active compound component for treating senile dementia and its prepn and use | |
| CN100349589C (en) | Medical application of rehmannia root extractive in resisting asthma and allergy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Guangdong Hengjian Pharmaceutical Co., Ltd. Assignor: Bencao Tian'gong Science & Tech. Co., Ltd., Jiangxi Contract record no.: 2010440000600 Denomination of invention: Compound longxuejie preparation, preparing technique and application Granted publication date: 20090204 License type: Exclusive License Open date: 20051116 Record date: 20100602 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090204 Termination date: 20160523 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |